decitabine dac combined with haag regimen targeting acute myeloid leukemia aml through epigenetic modulation and cytotoxic effects clinical trial intelligence

A Phase 3, Randomized, Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of Decitabine Combined With HAAG Regimen in Newly Diagnosed Acute Myeloid Leukemia Patients Younger Than 60 Years

This Phase 3 clinical trial is sponsored by The First Affiliated Hospital of Soochow University and aims to evaluate the efficacy and safety of Decitabine combined with the HAAG regimen in newly diagnosed AML patients under 60 years of age. The trial is currently recruiting participants and is expected to complete by May 2022. The market for AML treatments is competitive, with several existing therapies, including standard induction regimens like the IA regimen (Idarubicin plus Cytarabine). If successful, this trial could position Decitabine in a favorable light, potentially offering a novel treatment option that may improve overall response rates and survival outcomes, thus enhancing market share in the AML therapeutic landscape. Diligence should focus on the trial's ability to meet primary and secondary endpoints, as well as the safety profile compared to existing therapies.

Matched by target_normalized: Decitabine (DAC) combined with HAAG regimen targeting acute myeloid leukemia (AML) through epigenetic modulation and cytotoxic effects.